{"contentid": 488046, "importid": NaN, "name": "Biocad eyes production of its Forteka cancer drug in China", "introduction": "Russian biotech firm Biocad has confirmed it will begin clinical trials of its anti-cancer drug Forteka (prolgolimab) in China, with the aim of its possible production in that country, according to local media reports.", "content": "<p>Russian biotech firm Biocad has confirmed it will begin clinical trials of its anti-cancer drug Forteka (prolgolimab) in China, with the aim of its possible production in that country, according to local media reports.&nbsp;&nbsp;</p>\n<p>The trials will be conducted by a joint venture established between Biocad and China's Shanghai Pharmaceuticals Holding under the name of SPH Biocad.</p>\n<p>Intended for the treatment of melanoma, Biocad has been developing Forteka since 2013 and, according to Russian Vedomosti business paper, the company has already invested 737.2 million roubles (~$10 million) in its development.&nbsp;</p>\n<h2><strong>Ownership and investment in the JV</strong></h2>\n<p>The SPH Biocad joint venture was established two years ago with a capitalization of $400 million. Of this amount, $200.4 was invested by Shanghai Pharmaceuticals Holding, which received a 50.1% stake in the JV. The remaining stake is owned by Biocad, which contributed $29.94 million to the venture.</p>\n<p>Under the terms of the agreement, the Russian company also obtained permanent and exclusive rights on the production and distribution of six drugs for the treatment of cancer and autoimmune diseases (prolgolimab, netakimab, bevacizumab, trastuzumab, adalimumab, anti-GITR MAb).&nbsp;</p>\n<p>According to a representative of Biocad, the beginning of the trials is scheduled for second-quarter 2021, with planned investments amounting to $35 million. This is the first drug developed by the Russian company for which clinical trials will be conducted in China. The drug is currently being researched in Europe (Hungary and Slovakia), where volunteers are being recruited.</p>\n<p>In the event of successful tests, the production of the drug could be launched within the territory of China. Planned production volumes as well as estimated sales of the drug are not disclosed and will mainly depend on the level of demand in the local market.&nbsp;</p>\n<h2><strong>Growing interest in conducting clinical trials in China</strong></h2>\n<p>In the meantime, according to Svetlana Zavidova, executive director of the Association of Clinical Research Organizations in Russia, in China the number of approved clinical trials has been actively growing in over the past six-seven years, while the growth is currently ongoing.&nbsp;</p>\n<p>According to Ms Zavidova, there are currently 6,322 clinical trials of different drugs underway in the China, which means the openness of the Chinese authorities to innovation contributes to the growth of attractiveness of the local market for foreign pharmaceutical companies.&nbsp;</p>", "date": "2021-03-15 17:26:00", "meta_title": "Biocad eyes production of its Forteka cancer drug in China", "meta_keywords": "Biocad, Clinical trials, Production, Forteka, China, Joint venture, Shanghai Pharma, SPH Biocad, Prolgolimab", "meta_description": "Biocad eyes production of its Forteka cancer drug in China", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-15 17:25:02", "updated": "2021-03-15 17:39:34", "access": NaN, "url": "https://www.thepharmaletter.com/article/biocad-eyes-production-of-its-forteka-cancer-drug-in-china", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "biocad_manufacturing.jpg", "image2id": "biocad_manufacturing_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Asia Pacific, Companies, mergers and acquisitions, Focus On, Production, Research, Russian market", "geography_tag": "China, Russia", "company_tag": "Biocad, Shanghai Pharmaceutical Holding, SPH Biocad", "drug_tag": "Forteka, prolgolimab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-15 17:26:00"}